Tofacitinib

Nov 02, 2017

US Market Report for Ankylosing Spondylitis Immunology Drugs 2018 - Unit Sales, ASPs, Market Value & Growth Trends

Oct 30, 2017

Lilly to Present New Data on Immunology Portfolio at ACR/ARHP Annual Meeting

Oct 23, 2017

US Rheumatologists Report that Use of Biologic/JAK Monotherapy in Rheumatoid Arthritis is Greatest for Pfizer's Xeljanz, Roche/Genentech's Actemra, and Sanofi/Regeneron's Recently Launched Kevzara

Oct 20, 2017

US Rheumatologists Teed Up for Rapid Adoption of BMS' Orencia in Psoriatic Arthritis, Though the Real Game Changer Could Come with the Approval of Pfizer's Xeljanz

Sep 26, 2017

Analysis of Over 1000 Psoriatic Arthritis (PsA) Patients Reveals Large Candidate Pool for Pfizer's Xeljanz, BMS' Orencia, and Eli Lilly's Taltz

Sep 11, 2017

AbbVie's Upadacitinib (ABT-494) Meets All Primary and Ranked Secondary Endpoints in Second Phase 3 Study in Rheumatoid Arthritis

Aug 15, 2017

Novartis' Cosentyx Beginning to Plateau in Psoriatic Arthritis, as US Rheumatologists Prepare for an Influx of Non-TNF Agents, Such as BMS' Orencia, Pfizer's Xeljanz, and Lilly's IL-17, Taltz